Table 3.
Pol β protein expression and ER positive breast cancer (n = 1009).
| Variable | Pol β protein expression | P‐valve | |
|---|---|---|---|
| Low N (%) | High N (%) | ||
| A) Pathological parameters | |||
| Tumour size | |||
| <1 cm | 25 (7.6%) | 102 (15.0%) | 0.005 |
| >1–2 cm | 176 (53.7%) | 349 (51.2%) | |
| >2–5 cm | 117 (35.7%) | 219 (32.2%) | |
| >5 cm | 10 (3.0%) | 11 (1.6%) | |
| Tumour stage | |||
| 1 | 197 (59.9%) | 436 (63.8%) | 0.062 |
| 2 | 97 (29.5%) | 203 (29.7%) | |
| 3 | 35 (10.6%) | 44 (6.4%) | |
| Tumour grade | |||
| G1 | 53 (16.2%) | 158 (23.2%) | <0.001 |
| G2 | 112 (34.1%) | 304 (44.6%) | |
| G3 | 163 (49.7%) | 219 (32.2%) | |
| Mitotic index | |||
| M1 (low; mitoses < 10) | 109 (33.4%) | 341 (50.1%) | <0.001 |
| M2 (medium; mitoses 10–18) | 64 (19.6%) | 158 (23.2%) | |
| M3 (high; mitosis >18) | 153 (46.9%) | 181 (26.6%) | |
| Pleomorphism | |||
| 1 (Small‐regular uniform) | 8 (2.5%) | 26 (3.8%) | 0.020 |
| 2 (Moderate variation) | 138 (42.5%) | 342 (50.3%) | |
| 3 (Marked variation) | 179 (55.1%) | 312 (45.9%) | |
| Tubule formation | |||
| 1 (>75% of definite tubule) | 13 (4.0%) | 58 (8.5%) | 0.019 |
| 2 (10%–75% definite tubule) | 123 (37.7%) | 266 (39.1%) | |
| 3 (<10% definite tubule) | 190 (58.3%) | 356 (52.4%) | |
| Tumour type | |||
| IDC‐NST | 172 (59.1%) | 280 (47.5%) | 3.9 × 10−4 |
| Tubular carcinoma | 61 (21.0%) | 175 (29.7%) | |
| Medullary carcinoma | 4 (1.4%) | 0 (0.0%) | |
| ILC | 27 (9.3%) | 71 (12.0%) | |
| Others | 27 (9.3%) | 64 (10.8%) | |
| Lymphovascular invasion | |||
| No | 200 (61.9%) | 474 (70.0%) | 0.011 |
| Yes | 123 (38.1%) | 203 (30.0%) | |
| B) Aggressive phenotype | |||
| Her2 overexpression | |||
| No | 291 (90.7%) | 623 (93.8%) | 0.071 |
| Yes | 30 (9.3%) | 41 (6.2%) | |
| Cytokeratin 6 (CK6) | |||
| Negative | 261 (92.2%) | 546 (94.8%) | 0.138 |
| Positive | 22 (7.8%) | 30 (5.2%) | |
| Cytokeratin 14 (CK14) | |||
| Negative | 260 (92.5%) | 534 (93.5%) | 0.588 |
| Positive | 21 (7.5%) | 37 (6.5%) | |
| Cytokeratin 18 (CK18) | |||
| Negative | 16 (5.9%) | 12 (2.2%) | 0.007 |
| Positive | 253 (94.1%) | 524 (97.8%) | |
| C) Hormone receptors | |||
| PgR | |||
| Negative | 81 (26.6%) | 125 (19.3%) | 0.012 |
| Positive | 224 (73.4%) | 521 (80.7%) | |
| AR | |||
| Negative | 94 (34.6%) | 104 (19.4%) | 2.0 × 10−6 |
| Positive | 178 (65.4%) | 432 (80.6%) | |
| D) DNA repair | |||
| ATM | |||
| Absent | 104 (51.7%) | 194 (49.4%) | 0.583 |
| Normal | 97 (48.3%) | 199 (50.6%) | |
| BRCA1 | |||
| Absent | 58 (23.9%) | 52 (10.9%) | 5.0 × 10−6 |
| Normal | 185 (76.1%) | 424 (89.1%) | |
| XRCC1 | |||
| Low | 52 (21.6%) | 32 (6.6%) | <0.001 |
| High | 189 (78.4%) | 455 (93.4%) | |
| FEN1 | |||
| Low | 180 (79.3%) | 300 (66.5%) | 0.001 |
| High | 47 (20.7%) | 151 (33.5%) | |
| SMUG1 | |||
| Low | 84 (37.7%) | 121 (29.0%) | 0.025 |
| High | 139 (62.3%) | 296 (71.0%) | |
| E) Cell cycle/apoptosis regulators | |||
| MIB1 | |||
| Low | 103 (36.3%) | 266 (46.3%) | 0.005 |
| High | 181 (63.7%) | 308 (53.7%) | |
| P53 | |||
| Low expression | 227 (83.8%) | 493 (89.6%) | 0.016 |
| High expression | 44 (16.2%) | 57 (10.4%) | |
| Bcl‐2 | |||
| Negative | 80 (26.8%) | 109 (17.9%) | 0.002 |
| Positive | 218 (73.2%) | 499 (82.1%) | |
| TOP2A | |||
| Low | 125 (55.3%) | 203 (43.0%) | 0.002 |
| Overexpression | 101 (44.7%) | 269 (57.0%) | |
Grade as defined by NGS; BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; Basal‐like: ER−, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER−/PgR‐/HER2‐.